New breast cancer test predicts if disease could return

• A new test has been developed to predict whether breast cancer is likely to return just two weeks after treatment begins.
• Experts suggest this innovation could spare thousands of breast cancer patients from receiving unnecessary treatment.
• The test targets oestrogen receptor-positive, human epidermal growth factor receptor 2 positive breast cancer, a type accounting for around 200,000 global cases annually.
• Developed by scientists at The Institute for Cancer Research, London, the test identifies the 6 per cent of patients at highest risk of relapse.
• The findings aim to facilitate more precise and personalised treatment plans, guiding doctors on which patients need more intensive therapy.

IN FULL

Breast cancer breakthrough as new test could revolutionise treatment